This latest Invokana lawsuit was filed in the Philadelphia Court of Common Pleas, and includes allegations that Invokana maker Janssen Pharmaceuticals and its parent company, Johnson & Johnson, knew that the Type 2 diabetes drug could cause diabetic ketoacidosis in users, but failed to warn doctors and consumers of this risk. The case joins a growing number of product liability lawsuits filed over DKA and other alleged side effects of Invokana, which may include heart attack, abnormal weight loss, urinary tract infections, cardiovascular problems, kidney damage, kidney failure or wrongful death.
The most recent warning about a risk of diabetic ketoacidosis from Invokana was issued by the FDA on December 4, and indicated a change to the labels of SGLT2 inhibitors like Invokana, to reflect the risk of ketoacidosis and serious urinary tract infections associated with the drugs, both of which can result in hospitalization. According to the FDA warning, “Patients should stop taking their SGLT2 inhibitor and seek medical attention immediately if they have any symptoms of ketoacidosis,” which may include nausea, vomiting, fatigue, abdominal pain or difficulty breathing.
In its latest warning, the FDA stated that the agency had identified 73 cases of ketoacidosis in patients with Type 1 or Type 2 diabetes treated with SGLT2 inhibitors like Invokana between March 2013 and May 2015, all of which resulted in hospitalization or treatment in an emergency room. The agency also linked the use of SGLT2 inhibitors to 19 cases of life-threatening blood infections and kidney infections that began as urinary tract infections between March 2013 and October 2014, all of which resulted in hospitalization, with a few admissions to an intensive care unit or dialysis center for kidney failure treatment.
The FDA’s December warning followed a previous safety communication issued in May 2015, in which the agency indicated that “the type 2 medicines [Invokana], [Farxiga] and [Jardiance] may lead to ketoacidosis, a serious condition where the body produces high levels of blood acids called ketones that may require hospitalization.” At that time, the FDA had identified 20 cases of acidosis reported as diabetic ketoacidosis, ketoacidosis or ketosis in patients treated with Invokana or another SGLT2 inhibitor from March 2013 to June 6, 2014, all of which resulted in hospitalization to treat the ketoacidosis.
As more and more former Invokana users become aware of the potential for the Type 2 diabetes medication to cause diabetic ketoacidosis and other devastating side effects in users, a growing number of individuals are pursuing legal claims against Janssen Pharmaceuticals for damages including medical bills, lost wages, and pain and suffering. If you took Invokana or another SGLT2 inhibitor in the past, and you have since been diagnosed with diabetic ketoacidosis, ketoacidosis or ketosis, contact a knowledgeable product liability lawyer today to explore your possible compensation options.
Did you or a loved one suffer side effects from Invokana?
Find out if you qualify for compensation.
Get Your Free Case ReviewThis is an advertisement. This website is not affiliated with any pharmaceutical or medical device company or any trademarked product. Results are not guaranteed. This website provides a free matching service and is not responsible for information or services from third party providers. This website is associated with an advertising group that represents lawyers, it is not a law firm or referral service. Every case is different and services available will vary depending on state.